David F. Keren, MD, is a board-certified immunopathologist and clinical professor of pathology at the University of Michigan Health in Ann Arbor. As of early 2026, he continues to serve as a medical director within the Michigan Medicine system and as a trustee for the American Board of Pathology. Throughout his career, which began at the University of Michigan in 1978, he has specialized in the detection of monoclonal gammopathies and serum protein abnormalities.Â
Dr. Keren is widely recognized for his academic contributions, having authored over 160 peer-reviewed articles and 14 books, including his 2023 release, Electrophoresis and Mass Spectrometry. He holds a medical degree from the University of Illinois and completed his residency and postdoctoral training at The Johns Hopkins Hospital. In addition to his clinical and academic roles, he is the Chief Executive Officer of InheRET, Inc., a healthcare software company focused on inherited cancer risk assessment. Over the decades, his leadership has included serving as president of several major professional organizations, such as the American Society for Clinical Pathology and the Michigan Society of Pathologists